Who is sponsoring NCT02865083?

NCT02865083 is sponsored by St. Louis University.

What drugs are being tested in NCT02865083?

Interventions in NCT02865083: Traxi Pannus Retractor.

What condition does NCT02865083 study?

NCT02865083 studies Obese Patients Undergoing Cesarean Section.

Is NCT02865083 still recruiting?

NCT02865083 is currently terminated. Last updated 4 June 2018.

Are results published for NCT02865083?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-06-04 · How we verify

NCT02865083: Traxi

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of a Self-Retaining Pannus Retractor in Obese Patients Undergoing Cesarean Section

Terminated NA Results posted Last updated 4 June 2018

What this trial tests

NA trial testing Traxi Pannus Retractor in Obese Patients Undergoing Cesarean Section in 4 participants. Terminated before completion.

Timeline

1 June 2016

Primary endpoint
2 January 2017

2 January 2017

Quick facts

Lead sponsor	St. Louis University
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	4
Start date	1 June 2016
Primary completion	2 January 2017
Estimated completion	2 January 2017

Drugs / interventions tested

Traxi Pannus Retractor

Conditions studied

Obese Patients Undergoing Cesarean Section — all drugs for Obese Patients Undergoing Cesarean Section →

Sponsor

St. Louis University

Who can join

Adults 14 to 50, female only, with Obese Patients Undergoing Cesarean Section. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the effects of the Traxi Pannus retractor in obese patients (BMI ≥30 kg/m2) who undergo Cesarean sections compared to routine pannus retraction techniques. Patients will be randomized to the use of the Traxi retractor during Cesarean section (treatment group) or the use of traditional pannus retraction techniques (control group). The primary outcome to be followed is surgical site disruption. The investigators will also assess the duration of surgery or length of time from skin incision to delivery of the infant, change in hemoglobin, estimated blood loss, postoperative length of stay, need for hospital readmission or emergency room visits, or other complication rates between the two groups.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other St. Louis University trials

Trials by the same sponsor.

NCT07024940 — Short-term Effects of Caffeine and a Multi-ingredient Pre-workout on Exercise Performance · NA · recruiting
NCT06859528 — Step Up to PD: A Community-based Walking Program for People With Parkinson's Disease · NA · recruiting
NCT04158037 — Don't Go There: A Geospatial mHealth App for Gambling Disorder · NA · withdrawn
NCT05406310 — Clinical Outcomes of Persistent Atrial Fibrillation Ablation Using Ablation Index-guided Radiofrequency Catheter Ablatio · withdrawn
NCT05854836 — Preconception Intervention for Incarcerated Women With Substance Use · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02865083 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by St. Louis University
Last refreshed: 4 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02865083.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing